IN BRIEF: Regulators validate Bristol Myers' Opdivo extension

21st June 2024 19:18

Bristol-Myers Squibb Co - Princeton, New Jersey-based pharmaceutical company - Says the European Medicines Agency validated its extension application for a new subcutaneous route of administration for Opdivo, following its phase three CheckMate-67T trial. Also includes approval for new strength of 600 milligrams per vial. New application approval applies to the treatment of several solid tumors already approved for treatment with Opdivo.

Bristol Myers vice president Susan Parker says: "Subcutaneous nivolumab has the potential to change the way patients living with cancer receive Opdivo treatment and to significantly reduce administration time by utilizing a single injection in three-to-five minutes."

"We are committed to advancing medicines that improve the patient experience and are evaluating innovative formulations across our broad portfolio. We look forward to working with the EMA to advance this application with the goal of introducing the subcutaneous option of Opdivo."

Current share price: USD41.33, up 0.7% in New York on Friday afternoon

12-month change: down 37%

By Aidan Lane, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Get more news and expert articles direct to your inbox